Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps
Cancer Medicine · 2026
DOI: 10.1002/cam4.72251 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yixian Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Organoids, Neoplasms, Precision Medicine. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Background
Radiotherapy remains a cornerstone of cancer treatment, while its efficacy is often limited by tumor radioresistance and the risk of normal tissue toxicity. Conventional preclinical models, including two‐dimensional (2D) cell cultures and murine xenografts, exhibit significant limitations in recapitulating human tumor pathophysiology, thereby impeding the clinical translation of novel radiotherapeutic strategies. Patient‐derived organoids (PDOs) have emerged as transformative three‐dimensional (3D) ex vivo models that recapitulate key aspects of original tumor heterogeneity and are increasingly applied in oncology research.
Methods
This article provides a comprehensive review of the literature on the application of PDOs in radiation oncology, with a focused analysis of their pathway toward clinical translation.
Results
PDOs demonstrate significant utility in predicting radiosensitivity, elucidating radioresistance mechanisms, optimizing combination therapies, modeling radiation injury, and screening targeted drugs. The integration of organoid technology with microfluidic organ‐on‐a‐chip (OoC) platforms also offers unprecedented capability to dynamically simulate the tumor microenvironment and conduct high‐throughput dose‐response studies. A translational roadmap is presented for leveraging these biomimetic systems to advance personalized radiotherapy, ultimately aiming to accelerate the clinical translational application of organoids.
Conclusions
Despite challenges in standardization and immune component recapitulation, PDOs represent a powerful platform for advancing personalized radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Yixian Zhu
Förderung
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
Zitieren
APA
Zhu, Y., Jiao, Y., Xue, J., Lv, X., & Qin, S. (2026). Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps. Cancer Medicine. https://doi.org/10.1002/cam4.72251
Vancouver
Zhu Y, Jiao Y, Xue J, Lv X, Qin S. Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps. Cancer Medicine. 2026. doi:10.1002/cam4.72251
BibTeX
@article{Zhu2026,
author = {Zhu, Yixian and Jiao, Yawei and Xue, Jiao and Lv, Xiaoli and Qin, Songbing},
title = {Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72251}
}
EUVIMED